Hot Features
Premium
Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
Period:
Draw Mode:
| Volume | 119,733 |
|
|||||
| News | - | ||||||
| Day High | 4.58 | Low High |
|||||
| Day Low | 4.32 | ||||||
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| scPharmaceuticals Inc | SCPH | NASDAQ | Common Stock |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| 0.14 | 3.22% | 4.49 | 19:00:00 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 4.38 | 4.32 | 4.58 | 4.49 | 4.35 |
| Trades | Shares Traded | VWAP | Financial Volume | Average Volume | 52 Week Range |
|---|---|---|---|---|---|
| 1,293 | 119,733 | US$ 4.49 | US$ 537,677 | - | 4.25 - 12.75 |
| Last Trade | Type | Quantity | Price | Currency |
|---|---|---|---|---|
| 15:20:00 | formt | 224 | US$ 4.49 | USD |
scPharmaceuticals Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 161.88M | 36.05M | - | 13.59M | -54.81M | -1.52 | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
scPharmaceuticals News
| Date | Time | Source | News Article |
|---|---|---|---|
| 2/02/2024 | 11:35 | Edgar (US Regulatory) | Form SC 13G/A - Statement of acquisition of beneficial.. |
| 1/22/2024 | 19:28 | Edgar (US Regulatory) | Form 4 - Statement of changes in beneficial ownership of.. |
| 1/04/2024 | 16:30 | Edgar (US Regulatory) | Form 8-K - Current report |
| 1/03/2024 | 15:48 | Edgar (US Regulatory) | Form 4 - Statement of changes in beneficial ownership of.. |
| 11/08/2023 | 15:23 | Edgar (US Regulatory) | Form 10-Q - Quarterly report [Sections 13 or 15(d)] |
| 11/08/2023 | 15:05 | Edgar (US Regulatory) | Form 8-K - Current report |
| 9/20/2023 | 15:10 | Edgar (US Regulatory) | Form 8-K - Current report |
| 8/10/2023 | 15:14 | Edgar (US Regulatory) | Form 10-Q - Quarterly report [Sections 13 or 15(d)] |
| 8/10/2023 | 15:05 | Edgar (US Regulatory) | Form 8-K - Current report |
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical SCPH Price Data
| Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 4.50 | 4.79 | 4.27 | 4.50 | 129,042 | -0.01 | -0.22% |
| 1 Month | 4.97 | 5.33 | 4.25 | 4.79 | 172,666 | -0.48 | -9.66% |
| 3 Months | 5.03 | 6.54 | 4.25 | 5.30 | 220,936 | -0.54 | -10.74% |
| 6 Months | 5.84 | 6.71 | 4.25 | 5.41 | 294,122 | -1.35 | -23.12% |
| 1 Year | 9.50 | 12.75 | 4.25 | 7.45 | 316,023 | -5.01 | -52.74% |
| 3 Years | 6.80 | 12.75 | 3.48 | 7.04 | 229,912 | -2.31 | -33.97% |
| 5 Years | 3.65 | 12.75 | 2.78 | 6.98 | 172,319 | 0.84 | 23.01% |
scPharmaceuticals Description
| scPharmaceuticals Inc is a pharmaceutical company. Its pipeline includes products in various stages of clinical and non-clinical development. It focuses on pharmaceutical products in the cardiovascular and infectious disease therapeutic areas. The company's lead product is Furoscix. Furoscix consists of this patented formulation of furosemide for subcutaneous administration with wearable, portable sc2Wear Infusor for the treatment of edema in patients with heart failure. |
